Search results for " BURDEN"

showing 10 items of 325 documents

Corrigendum to “Polyvascular subclinical atherosclerosis in familial hypercholesterolemia: The role of cholesterol burden and gender” [Nutr Metab Car…

2019

International audience; Background and aim: Heterozygous familial hypercholesterolemia (HeFH) is a genetic disease characterized by a heterogeneous phenotype. The assessment of cardiovascular (CV) risk is challenging for HeFH. Cholesterol burden (CB) allows to estimate the lifelong exposure to high levels of cholesterol. The aim of this study was to analyze the distribution of subclinical athero-sclerosis and the relationship between atherosclerosis and the CB in a sample of HeFH patients, focusing on sex-related differences. Methods and Results: 154 asymptomatic HeFH subjects underwent coronary-artery-calcium score (CACs) and Doppler ultrasound of carotid and femoral arteries. Yearly lipid…

Peripheral arterial atherosclerosismedicine.medical_specialtyEndocrinology Diabetes and Metabolism[SDV]Life Sciences [q-bio]Medicine (miscellaneous)030209 endocrinology & metabolismFamilial hypercholesterolemia030204 cardiovascular system & hematologyCoronary artery calcium03 medical and health scienceschemistry.chemical_compound0302 clinical medicineInternal medicineMedicineNutrition and Dieteticsbusiness.industryCholesterolmedicine.diseaseAtherosclerosisCardiovascular diseaseCardiovascular riskCalcium score3. Good healthFamilial hyper cholesterolemiaCholesterol burdenchemistrySubclinical atherosclerosisCardiologyCardiology and Cardiovascular Medicinebusiness[SDV.AEN]Life Sciences [q-bio]/Food and Nutrition
researchProduct

Influence of Drugs on Mild Cognitive Impairment in Parkinson’s Disease: Evidence from the PACOS Study

2022

Background: Polytherapy and the anticholinergic activity of several drugs negatively influence cognition in the elderly. However, little is known on the effect on Mild Cognitive Impairment (MCI) in Parkinson’s Disease (PD). Methods: Patients with PD belonging to the baseline PACOS cohort with full pharmacological data, have been included in this study. MCI diagnosis was made according to the MDS level II criteria. Polytherapy was defined as patients assuming ≥6 drugs. Anticholinergic burden has been calculated using the Anticholinergic Drug Scale (ADS). Molecules have been classified according to the ATC classification. Association with MCI has been assessed with a multivariate logistic re…

PharmacologyParkinson DiseaseGeneral MedicineMiddle AgedNeuropsychological TestspolytherapydrugsCholinergic Antagonistsanticholinergic burdenPsychiatry and Mental healthmild cognitive impairmentNeurologyParkinson’s diseaseHumansSettore MED/26 - NeurologiaCognitive DysfunctionPharmacology (medical)Neurology (clinical)polypharmacyAgedCurrent Neuropharmacology
researchProduct

Phantom size in brachytherapy source dosimetric studies

2004

An important point to consider in a brachytherapy dosimetry study is the phantom size involved in calculations or experimental measurements. As pointed out by Williamson [Med. Phys. 18, 776-786 (1991)] this topic has a relevant influence on final dosimetric results. Presently, one-dimensional (1-D) algorithms and newly-developed 3-D correction algorithms are based on physics data that are obtained under full scatter conditions, i.e., assumed infinite phantom size. One can then assume that reference dose distributions in source dosimetry for photon brachytherapy should use an unbounded phantom size rather than phantom-like dimensions. Our aim in this paper is to study the effect of phantom s…

Photonmedicine.medical_treatmentBrachytherapyMonte Carlo methodBrachytherapyModels BiologicalSensitivity and SpecificityImaging phantomRelative biological effectivenessmedicineHumansScattering RadiationDosimetryComputer SimulationPoint (geometry)RadiometryRadioisotopesPhysicsPhantoms Imagingbusiness.industryRadiotherapy Planning Computer-AssistedReproducibility of ResultsRadiotherapy DosageGeneral MedicineRadiusComputational physicsOrgan SpecificityBody BurdenRadiopharmaceuticalsNuclear medicinebusinessMonte Carlo MethodAlgorithmsRelative Biological EffectivenessMedical Physics
researchProduct

Heterogeneous contributions of change in population distribution of body mass index to change in obesity and underweight

2021

From 1985 to 2016, the prevalence of underweight decreased, and that of obesity and severe obesity increased, in most regions, with significant variation in the magnitude of these changes across regions. We investigated how much change in mean body mass index (BMI) explains changes in the prevalence of underweight, obesity, and severe obesity in different regions using data from 2896 population-based studies with 187 million participants. Changes in the prevalence of underweight and total obesity, and to a lesser extent severe obesity, are largely driven by shifts in the distribution of BMI, with smaller contributions from changes in the shape of the distribution. In East and Southeast Asia…

Population -- Health aspectsLeannessBaixo peso/UnderweightnoneDouble burdenalipainoisuustulotasoglobal healthsystematic analysisSedentary behaviorsRC1200Prospective associations0302 clinical medicineunderweightnälänhätäBiology (General)skin and connective tissue diseasesChildrenComputingMilieux_MISCELLANEOUSBody mass indexHuman Nutrition & Healtheducation.field_of_studyHumane Voeding & GezondheidylipainoGeneral Medicinekansainvälinen vertailu3. Good healthWorld healthMedicineA100 Pre-clinical MedicinePopulation distributionmedicine.medical_specialtyQH301-705.5ScienceSocio-culturaleNursing.Social sciencesGeneral Biochemistry Genetics and Molecular Biology03 medical and health sciencesThinnessSDG 3 - Good Health and Well-beingBMI; epidemiology; global health; none; obesity; underweightNoneHumansObesidade/ObesitySDG 2 - Zero HungereducationVLAGUS adultsOmvårdnadbody mass index; malnutrition; obesity underweightnutritional and metabolic diseasesmedicine.diseaseterveellisyysObesityFaculdade de Ciências SociaisBMI; epidemiology; global health; none; obesity; underweight; Body Mass Index; Humans; Obesity; Prevalence; Risk Factors; ThinnessGeneral BiochemistryWIASlihavuusunderweight ; obesity ; BMIBody mass indexRADemographyN.A.double burdenobesitySettore MED/09 - Medicina Internaalueelliset erotNutrition and DiseaseAnimal Nutrition[SDV]Life Sciences [q-bio]Medizin030204 cardiovascular system & hematology0601 Biochemistry and Cell BiologyChange distribution of body mass indexRisk FactorsRA0421Voeding en ZiekteEpidemiologyPrevalenceMedicine and Health SciencesGlobal healthÍndice de massa corporal/Body Mass Index030212 general & internal medicineUnderweightpainoindeksi2. Zero hungerGeneral NeuroscienceQRaliravitsemuselintarvikkeethealthPublic Health Global Health Social Medicine and EpidemiologyDiervoeding3142 Public health care science environmental and occupational health//purl.org/pe-repo/ocde/ford#3.01.03 [https]/dk/atira/pure/sustainabledevelopmentgoals/good_health_and_well_beingChinese adultsepidemiologypooled analysisUnderweightmedicine.symptomDiet qualityB120 PhysiologyResearch Articletrends//purl.org/pe-repo/ocde/ford#1.06.03 [https]prevalencePopulationMothersGenetics and Molecular Biologybody mass indexmalnutrition3121 Internal medicineBMImedicineLife Scienceddc:6103125 Otorhinolaryngology ophthalmologyObesitykehonkoostumusNutritionAustralian adultsGeneral Immunology and Microbiology//purl.org/pe-repo/ocde/ford#3.01.04 [https]Ciências sociaisFolkhälsovetenskap global hälsa socialmedicin och epidemiologiMalnutritionEpidemiology and Global Healthsense organsEstilos de Vida e Impacto na Saúde
researchProduct

2018

Summary Background The Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2017 comparative risk assessment (CRA) is a comprehensive approach to risk factor quantification that offers a useful tool for synthesising evidence on risks and risk–outcome associations. With each annual GBD study, we update the GBD CRA to incorporate improved methods, new risks and risk–outcome pairs, and new data on risk exposure levels and risk–outcome associations. Methods We used the CRA framework developed for previous iterations of GBD to estimate levels and trends in exposure, attributable deaths, and attributable disability-adjusted life-years (DALYs), by age group, sex, year, and location fo…

Population ageingeducation.field_of_studybusiness.industryPopulationGeneral MedicineEnvironmental exposure030204 cardiovascular system & hematology3. Good health03 medical and health sciences0302 clinical medicineRelative riskEnvironmental healthLife expectancyMedicine030212 general & internal medicineRisk factorbusinessRisk assessmenteducationDisease burdenThe Lancet
researchProduct

Introduction and Psychometric Validation of the Resilience and Strain Questionnaire (ResQ-Care)— A Scale on the Ratio of Informal Caregivers' Resilie…

2021

Background: Informal caregivers are a particularly vulnerable population at risk for adverse health outcomes. Likewise, there are many scales available assessing individual caregiver burden and stress. Recently, resilience in caregivers gained increasing interest and scales started to assess resilience factors as well. Drawing on a homeostatic model, we developed a scale assessing both caregivers' stress and resilience factors. We propose four scales, two covering stress and two covering resilience factors, in addition to a sociodemographic basic scale. Based on the stress:resilience ratio, the individual risk of adverse health outcomes and suggestions for interventions can be derived.Metho…

Psychiatrystress awarenessDiscriminant validityRC435-571Perceived Stress ScalehealthCaregiver burdenExploratory factor analysisPsychiatry and Mental healthcounselingCronbach's alphapreventionScale (social sciences)homeostasisdiagnosticsGeriatric Depression ScalePsychologyResilience (network)Original ResearchClinical psychologyFrontiers in Psychiatry
researchProduct

Anemia prevalence in women of reproductive age in low- and middle-income countries between 2000 and 2018

2021

Anemia is a globally widespread condition in women and is associated with reduced economic productivity and increased mortality worldwide. Here we map annual 2000–2018 geospatial estimates of anemia prevalence in women of reproductive age (15–49 years) across 82 low- and middle-income countries (LMICs), stratify anemia by severity and aggregate results to policy-relevant administrative and national levels. Additionally, we provide subnational disparity analyses to provide a comprehensive overview of anemia prevalence inequalities within these countries and predict progress toward the World Health Organization’s Global Nutrition Target (WHO GNT) to reduce anemia by half by 2030. Our results …

Psychological interventionDiseasesResearch & Experimental MedicineGlobal HealthPrevalence11 Medical and Health Sciencesmedia_commonCHILD GROWTH FAILUREPublic Health Global Health Social Medicine and EpidemiologyAnemiaGeneral MedicineMiddle AgedanemiaPeer reviewIRON-DEFICIENCYNutritional StatuPREGNANCYMedicine Research & ExperimentalScale (social sciences)reproductive age/dk/atira/pure/sustainabledevelopmentgoals/good_health_and_well_beingA990 Medicine and Dentistry not elsewhere classifiedFemalewomenLife Sciences & Biomedicinevulnerable populationsHumanAdultmedicine.medical_specialtyBiochemistry & Molecular BiologyInequalityAdolescentAnemiamedia_common.quotation_subjectMODELSImmunologyNutritional StatusReproductive ageLocal Burden of Disease Anaemia CollaboratorsGeneral Biochemistry Genetics and Molecular BiologyDeveloping CountrieYoung AdultSDG 3 - Good Health and Well-beingEnvironmental healthmedicineLife ScienceHumansDeveloping CountriesPovertyGlobal NutritionPregnancyWereldvoedingScience & Technologybusiness.industryPublic healthCell BiologyGLOBAL BURDENmedicine.diseaseFolkhälsovetenskap global hälsa socialmedicin och epidemiologiRisk factors1182 Biochemistry cell and molecular biology3111 Biomedicinebusiness
researchProduct

A model for estimating the health economic impact of earlier diagnosis of chronic thromboembolic pulmonary hypertension

2021

Background Diagnostic delay of chronic thromboembolic pulmonary hypertension (CTEPH) exceeds 1 year, contributing to higher mortality. Health economic consequences of late CTEPH diagnosis are unknown. We aimed to develop a model for quantifying the impact of diagnosing CTEPH earlier on survival, quality-adjusted life-years (QALYs) and healthcare costs. Material and methods A Markov model was developed to estimate lifelong outcomes, depending on the degree of delay. Data on survival and quality of life were obtained from published literature. Hospital costs were assessed from patient records (n=498) at the Amsterdam UMC – VUmc, which is a Dutch CTEPH referral center. Medication costs were ba…

Pulmonary and Respiratory Medicine7medicine.medical_specialtyRespiratory SystemImproved survival610 Medicine & healthQuality of lifeQUALITY-OF-LIFEOriginal Research ArticlesHealth caremedicineEconomic impact analysisIntensive care medicineANGIOPLASTYEconomic consequencesDisease burdenPulmonary Vascular DiseaseScience & Technologybusiness.industry10031 Clinic for AngiologyR2740 Pulmonary and Respiratory MedicineReferral centerMedicineChronic thromboembolic pulmonary hypertensionbusinessLife Sciences & Biomedicine
researchProduct

Informal caregiving burden in advanced non-small cell lung cancer: the HABIT study.

2007

Introduction This study's aim was to assess economic data regarding the home assistance burden for advanced non-small cell lung cancer (NSCLC) patients in Italy. Patients and Methods One hundred four NSCLC patients in second-line chemotherapy (2LC) or in supportive therapy (ST) were enrolled in 18 Italian oncology departments and were observed for 3 months. The main caregiver's workload was assessed monthly by a task scale; other caregivers' activities were also registered. Eastern Cooperative Oncology Group performance status was assessed by physicians, and patients completed the Lung Cancer Symptoms (LCS) subscale. Formal caregiving time was valued according to market prices; informal car…

Pulmonary and Respiratory MedicineAdultMalemedicine.medical_specialtyLung NeoplasmsHome Nursingmedia_common.quotation_subjectAntineoplastic Agentscaregiving burden in advanced non-small cell lung cancerNSCLCQuality of lifeCost of IllnessCarcinoma Non-Small-Cell LungmedicineHumansLung cancermedia_commonAgedAged 80 and overbusiness.industrySocial SupportWorkloadAssistance burdenHealth Care CostsMiddle Agedmedicine.diseaseOncologyCaregiversItalySocioeconomic FactorsInformal caregivingSpouseSupportive psychotherapyScale (social sciences)Family medicinePhysical therapyCosts and Cost AnalysisQuality of LifeFemaleHabitNon small cellbusiness
researchProduct

Progress in the management of acute pulmonary embolism.

2015

Purpose of review Pulmonary embolism is a major contributor to global disease burden worldwide. The 2014 guidelines of the European Society of Cardiology, endorsed by the European Respiratory Society, emphasize the need for initial and advanced risk stratification as well as risk-adapted treatment to ensure the highest quality of care. This review summarizes the progress in pulmonary embolism diagnosis, risk assessment, and treatment. Recent findings Major advances of the past 12 months include age-related biomarker cutoff levels for optimising pulmonary embolism diagnosis and risk stratification; detection of (isolated) subsegmental pulmonary embolism by computed tomographic pulmonary angi…

Pulmonary and Respiratory MedicineVena cava filtersmedicine.medical_specialtybusiness.industryMEDLINEAnticoagulantsDiseasemedicine.diseaseRisk AssessmentPulmonary embolismFibrinolytic AgentsmedicinePulmonary angiographyBiomarker (medicine)HumansThrombolytic TherapyRisk assessmentbusinessIntensive care medicinePulmonary EmbolismDisease burdenBiomarkersCurrent opinion in pulmonary medicine
researchProduct